What are the typical presentation, diagnostic workup, and first‑line treatment for pediatric myositis (juvenile dermatomyositis and juvenile polymyositis)?

Pediatric Myositis: Presentation, Diagnosis, and Treatment

Clinical Presentation

Juvenile dermatomyositis (JDM) presents with the combination of proximal muscle weakness and characteristic skin findings, while juvenile polymyositis (JPM) is exceedingly rare and requires muscle biopsy confirmation to exclude other diagnoses. 1

Key Clinical Features

Muscle manifestations:

• Symmetric proximal muscle weakness affecting upper and lower extremities (shoulder and hip girdle muscles) 1, 2
• Neck flexor weakness (relatively weaker than neck extensors) 2
• Myalgia and muscle tenderness 3
• Dysphagia with cricopharyngeal dysfunction (prominent feature, poor prognostic sign) 1, 4
• Severe disability may manifest as inability to get off bed or CMAS score <15 1

Pathognomonic skin findings in JDM:

• Heliotrope rash (violaceous periorbital edema) - present in 100% of cases 5, 6
• Gottron papules (erythematous papules over extensor surfaces of joints) - present in 96% 5, 6
• Gottron sign (erythematous macules without papules over joints) 1, 2
• Periungual telangiectasias and nailfold capillary abnormalities 1, 6
• Erythroderma (88% of cases) 5

Extramuscular manifestations:

• Constitutional symptoms: fever, weight loss, fatigue 1, 4
• Calcinosis cutis (38% at presentation, more common with delayed treatment) 1, 5
• Gastrointestinal vasculopathy leading to bowel ischemia/infarction 1
• Interstitial lung disease (8% of patients, significant cause of mortality) 1, 4
• Cardiac involvement: pericarditis, myocarditis, arrhythmias 1, 4

Critical pitfall: Muscle enzymes (CK) may be normal in JDM despite active disease, particularly when skin involvement dominates—do not exclude the diagnosis based on normal CK alone. 4, 7

Diagnostic Workup

Initial Laboratory Evaluation

All suspected cases require: 1, 2

• Muscle enzymes: creatine phosphokinase (CPK), lactate dehydrogenase (LDH), AST, ALT, aldolase
• Complete blood count with differential
• Erythrocyte sedimentation rate and C-reactive protein
• Comprehensive metabolic panel
• Myositis-specific and myositis-associated autoantibody panel 1, 4

Key autoantibodies and their significance: 4

• Anti-NXP2: high cancer risk in adults, calcinosis in children
• Anti-TIF1γ: high malignancy risk in adults ≥40 years
• Anti-Mi2: classic dermatomyositis with good treatment response
• Anti-MDA5: rapidly progressive interstitial lung disease (requires urgent evaluation)
• Anti-Jo-1 and other antisynthetase antibodies: antisynthetase syndrome with ILD

Muscle Assessment

Validated muscle strength testing is mandatory: 1

• Childhood Myositis Assessment Scale (CMAS) - note that children <9 years may not achieve maximum score of 52 1
• Manual Muscle Test-8 (MMT-8) 1

MRI of proximal muscles: 1

• T2-weighted fat-suppressed sequences to detect muscle inflammation
• Reliable for diagnosis and differentiating active from inactive disease
• Increasingly preferred over muscle biopsy (89.9% vs 36-65% usage) 1

Muscle biopsy indications: 1

• Atypical presentation or diagnostic uncertainty
• To exclude metabolic/mitochondrial myopathies or dystrophies
• Use standardized JDM biopsy scoring tool
• JDM shows perivascular inflammatory infiltrates and perifascicular atrophy 3
• JPM shows endomysial inflammatory infiltrates 3

EMG/nerve conduction studies: 1

• Only when diagnosis is uncertain
• Does not reliably detect metabolic myopathies
• Decreasing usage (7.6-55.5%) in favor of MRI 1

Skin Assessment

Nailfold capillaroscopy should be performed at diagnosis and follow-up: 1

• Can be done with otoscope, ophthalmoscope, or dermatoscope
• Capillary density is sensitive measure of disease activity
• Persistent capillary abnormalities predict longer time to remission 1

Organ-Specific Screening

Pulmonary assessment (all patients at diagnosis): 1

• Pulmonary function tests including DLCO
• Chest radiography
• High-resolution CT if symptoms, abnormal PFTs, or risk factors present
• Anti-MDA5 positivity mandates urgent ILD evaluation 4

Cardiac screening: 1

• Baseline ECG and echocardiography
• Monitor for pericarditis, myocarditis, arrhythmias
• Systolic/diastolic dysfunction may be asymptomatic 1

Critical pitfall: Do not diagnose juvenile polymyositis without muscle biopsy confirmation—many cases represent immune-mediated necrotizing myopathy, overlap syndromes, or metabolic conditions. 4, 3

First-Line Treatment

High-Risk Patients Requiring Immediate Referral

Urgent transfer to specialized center if any of the following: 1

• Severe disability (inability to get off bed)
• CMAS score <15 or MMT8 score <30
• Aspiration or dysphagia preventing swallowing
• Gastrointestinal vasculitis (bloody stools or imaging evidence)
• Myocarditis
• Parenchymal lung disease
• CNS involvement (decreased consciousness or seizures)
• Skin ulceration
• ICU-level care required
• Age <1 year

Standard Initial Therapy

For mild to moderate active muscle disease: 2, 5

• High-dose oral prednisone (1-2 mg/kg/day, maximum 60-80 mg/day) in combination with methotrexate (10-15 mg/m²/week, maximum 25 mg/week)
• This combination is the cornerstone of management 2, 5

For severe disease or poor oral response: 2, 5

• Pulse intravenous methylprednisolone (30 mg/kg/day, maximum 1 gram/day for 3 consecutive days)
• Followed by high-dose oral prednisone plus methotrexate
• Preferred for gastrointestinal vasculopathy 2

For refractory or severe disease: 2, 5

• Add cyclosporine (used in 48% of refractory cases) 5
• Cyclophosphamide reserved for severe ILD or contraindications to methotrexate 2

For rapidly progressive ILD (especially anti-MDA5 positive): 4

• Add cyclophosphamide or rituximab to high-dose corticosteroids immediately

Treatment Monitoring

Disease activity assessment using validated tools: 1

• Disease Activity Score (DAS) for skin and overall activity
• CMAS and MMT-8 for muscle strength
• Patient/parent-reported outcome measures (Childhood Health Assessment Questionnaire, visual analogue scales) 1

Disease damage assessment: 1

• Myositis Damage Index annually
• Monitor for calcinosis, muscle atrophy, lipodystrophy

Critical pitfall: Risk of calcinosis and lipodystrophy increases with prolonged active disease and inadequate corticosteroid therapy—early aggressive treatment is essential. 1, 2

Prognosis

With early aggressive treatment: 1, 2

• 30-50% achieve remission within 2-3 years
• Mortality rate <4%
• However, 41-60% have polycyclic or persistently active disease 1

Poor prognostic factors: 4

• Dysphagia
• Cardiac involvement
• Severe interstitial lung disease
• Delayed diagnosis and treatment initiation 5